Two years ago South African company MJ MEDTECH a subsidiary of WUHAN GENERAL GROUP INC. announced plans to enter psychedelic sector after successful cannabis and CBD endeavors. Tests are now complete for rat and cell line trials, with the focus now being pushed towards analyzing the data and putting it into meaningful words that can show the true applications of psilocybin, which is produced by specific types of mushrooms that originate from spores. They are testing for brain chemistry, inflammation, overall health and long term affects. The goal of these studies is to prove the efficacy of psilocybin as a treatment for mental health (ptsd, depression, anxiety, etc) as well as other physical ailments (high blood pressure, brain inflammation etc). Human trials are now being scheduled in accordance with Covid 19 limitations. They currently have several successful cannabis products and will follow suit with extracts and fruiting bodies when testing is complete.
Related Articles
Leopoldo Salazar Viniegra: A Psychiatrist Ahead of His Time
Leopoldo Salazar Viniegra piloted one of the most forward thinking approaches to drug policy of the 21st century. In the 1930’s, he was one of Mexico’s leading psychiatrists and advocated a radical “social medicine” treatment approach. Alongside notable figures like...
Psilocybin in Science Before Prohibition: A Forgotten History
When we speak of this current moment, as psychedelics undergo an alleged “renaissance”, we often ignore a past that many people never learned. It’s a past in which psilocybin was a legitimate pharmaceutical, sold under a brand name and distributed by one of the...
Psilocybe ochraceocentrata – Hidden in Plain Sight
If you follow the world of magic mushroom microscopy, you've almost certainly encountered the spores of Natal Super Strength or Transkei. They're among the most popular specimens in the hobby, studied by enthusiasts and researchers alike. Like pretty much everyone...